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Abstract 
Post-transplant lymphoproliferative disorders 
(PTLDs) are serious, life-threatening complications 
of transplantation, which represent a heterogeneous 
group of lymphoproliferative diseases and show a 
spectrum of clinical, morphologic, and molecular 
genetic features ranging from reactive polyclonal 
lesions to frank lymphomas. Polymorphic(P) PTLD 
are composed of immunoblasts, plasma cells and 
small and intermediate-sized lymphoid cells that 
efface the architecture of lymph nodes or form 
destructive extranodal masses and do not fulfill the 
criteria for any of the recognized types of lymphoma 
described in immunocompetent hosts, which shows 
characteristic clinicopathological features and 
molecular involvement. 
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Clinics and pathology 
Disease 
The term "post-transplant lymphoproliferative 
disorder" or disease (PTLD) was first introduced in 
1984 by Starzl (Starzl et al.1984). PTLDs are 
serious, life-threatening complications of solid-
organ transplantation (SOT) and bone marrow 
transplantation, and are associated with high 
mortality. PTLDs represent a heterogeneous group 
of lymphoproliferative diseases, which show a 
spectrum of clinical, morphologic, and molecular 
genetic features ranging from reactive polyclonal 
lesions to frank lymphomas. . 
PTLDs are classified into early lesions, 
polymorphic, monomorphic, and classical Hodgkin's 
lymphoma-like PTLD. 
P-PTLD shows characteristic clinicopathological 
features and molecular involvement. P- PTLD are 
composed of immunoblasts, plasma cells and small 
and intermediate-sized lymphoid cells that efface the 
architecture of lymph nodes or form destructive 
extranodal masses and do not fulfill the criteria for 
any of the recognized types of lymphoma described 
in immunocompetent hosts (Swerdlow, et al ,2008. 
Mucha, et al. 2010.) 
Phenotype/cell stem origin 
The majority (>90%) of PTLD in solid organ 
recipients are of host origin and only a minority of 
donor origin. Donor origin PTLD appear to be most 
common in liver and lung allograft recipients, and 
frequently involve the allograft. In contrast, the 
majority of PTLD in bone marrow (BM) allograft 
recipients are of donor origin, as would be expected, 
since successful engraftment results in an immune 
system that is nearly exclusively of donor origin 
(Chadbum, et al ,1995. Swerdlow, et al ,2008). 
Phenotypically, P- PTLD cases show B cells with or 
without light chain class restriction and a variable 
proportion of heterogeneous T cells that sometimes 
predominate. Light chain class restriction, when 
present, may be focal, and some cases may 
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demonstrate different clonal populations in the same 
or different sites. Cases with clearcut light chain 
class restriction should be differentiated from 
monomorphic PTLD,Reed-Sternberg-like cells 
when present are often CD30+,CD20+ but CD15-
.Most cases of P-PTLD contain numerous EBER-
positive cells (Swerdlow, et al ,2008. Dunphy CH, et 
al, 2002). 
Epidemiology 
The incidence of PTLD ranges from 1-3 % in renal 
to 5-20 % in lung and intestinal transplantation, 
related to the type of transplanted organ, intensity of 
IS, age, and viral infection, etc ( Opelz, 2003. 
Opelz,1993.) In contrast, the incidence of PTLD 
after BMT is about 1.0 % for recipients from HLA-
compatible related donors (lower than that of SOT), 
but in up to 25 % for high-risk patients (Curtis, 1999) 
. However, the field has evolved during the last 
decade. Hoegh-Petersen et al. found a frequency of 
8.1 % among 307 allo-HSCT recipients who had also 
received ATG-based conditioning. Kamani et al. 
found an overall incidence of 2.3 % for post-
transplant malignancy (most of which were PTLD) 
in patients receiving such transplant for primary 
immunodeficiency disorders. The highest subgroup, 
those patients with Wiskott-Aldrich syndrome, had a 
3.3 % frequency. 
In our hospital, it is 1.5 % (9/585) from August 2002 
to October 2006 and about 1 % (9/857) from 
November 2006 to November 2009 after allo-HSCT, 
respectively. The incidence of PTLD was higher in 
mismatched or unrelated HSCT group than that of 
conventional one, 3.4 % (7/208), 2.3 % (1/44) versus 
0/323. It was also higher in patients with 
conditioning regimen including ATG than those 
without, 3.4 % (9/262) vs. 0/323 (Swerdlow, et al 
,2008. Chen, 2013). 
Clinics 
The clinical features of PTLD differ from those of 
lymphomas observed in the general population. 
Symptoms may be mild, such as fever, 
mononucleosis-like syndrome, lymphadenopathy, 
recurrent infections or severe organ dysfunction. The 
variable manifestation of PTLD depends on many 
factors, such as the type of transplanted organ or IS 
used, histopathology and time elapsed since 
transplantation. The first year after transplantation is 
important, in lung recipients, more than 50 % of all 
PTLDs develop during the first post-transplant year. 
Our data showed that 88.2 % of patients (15/17) were 
diagnosed within 7 months after transplantation (1.5-
7 months), and the median interval after 
transplantation to the diagnosis was 2.5 months 
(mean 4.7 months, range 1.5-19 months), shorter 
than that of SOT. The frequent sites of PTLD include 
GI (jejunum more often than colon), lymph nodes, 
and central nervous system, different from type to 
type of transplantation. 
The frequency of P-PTLD is different from one 
institution to another, ranging from 20% to over 80% 
of the cases. P-PTLD is most commonly seen in 
children, the clinical presentation of which is same 
to PTLD in general (Opelz, et al, 2003. Swerdlow, et 
al ,2008. Johnson, et al, 2006.Nelson, et al, 2000. 
Webber , et al ,2006). 
Pathology 
P-PTLD is characterized by effacement of the 
architecture and full range of B-cell maturation from 
immunoblasts to plasma cells, with lymphocytes and 
Hodgkin and Reed-Sternberg (HRS)-like cells. P-
PTLD was proposed to separate into polymorphic B-
cell hyperplasias and polymorphic B-cell lymphoma, 
the former composed of a mixture of lymphoid cells 
with prominent plasmacytoid differentiation and 
abundant immunoblasts without cytologic atypia, in 
which necrosis was limited to single cells or small 
foci, whereas the latter lacking prominent 
plasmacytoid differentiation with significant 
cytologic atypia, atypical immunoblasts, and large 
confluent coagulative areas of necrosis.(Knowles, et 
al, 1995). 
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Figure 1.  Polymorphic PTLD. Effacement of the architecture and proliferative lymphoid cells. (HE stain) 
 
 
Figure 2.  There is a polymorphic proliferation of immunoblasts, small lymophoid cells and plasma cells, with 
lymphocytes and HRS-like cells 
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Figure 3.  Full range of B-cell maturation from immunoblasts to plasma cells. 
 
 
Figure 4.  Some cells are positive for CD20. 
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Figure 5.  Some cells are positive for CD3. 
 
 
Figure 6.  Plasma cells are positive for CD38. 
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Figure 7.  Some plasma cells are positive for Kappa 
 
 
Figure 8.  Some plasma cells are positive for Lambda.There is no light chain restriction can be seen. 
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Figure 9.  The proliferation index of Ki 67 is 95%. 
 
 
Figure 10.  The immunoblasts were positive for CD30, variable in staining intensity. 
Treatment 
There is no consensus on the optimal treatment of 
PTLD. It is generally agreed that three major 
strategies should be applied: restoration of the 
recipient's immunity (to limit the EBV infection), 
elimination EBV and removal of neoplastic B cells. 
Reduction of IS or even withdrawal remains the first-
line treatment. With reduction of  
 
immunosuppression, virtually all early lesions 
regress and generally show good prognosis, whereas 
half of P-PTLD regress and some will progress, the 
majority of M-PTLDs do not regress. DLI was 
effectively used in EBV-associated PTLD after 
mismatched/haploidentical haematopoietic stem cell 
transplantation (HSCT) . Patients with lymph node 
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localization have a relatively good outcome, and 
disseminated disease in contrast has a poor prognosis 
( Mucha, et al, 2010. Xu, et al, 2010). 
Prognosis 
The prognosis of PTLD is poor. The treatment of 
rejection episodes with OKT3 or ATG enhances the 
PTLD risk in patients who did not receive antibody 
induction, rejection therapy with OKT3 or ATG adds 
to the already increased lymphoma risk HLA 
matching is also a risk factor in the pathogenesis of 
PTLD, and HLA-B or HLA-DR mismatches 
especially seem to be critical. The number of HLA 
mismatches parallels with an increased risk of PTLD 
(Opelz, et al, 2003. Opelz, et al, 2010). 
Genetics 
Note 
P-PTLD are expected to demonstrate clonally 
rearranged immunoglobulin genes although the 
clones are less predominant than in monomorphic 
PTLD. Seventy-five percent of P-PTLD are reported 
to have mutated immunoglobulin gene variable 
regions without ongoing mutations and the 
remainder are unmutated. BCL6 somatic 
hypermutations may be present as well as aberrant 
promoter methylation, but other oncogene 
abnormalities are not detected (Swerdlow, et al 
,2008. Capello ,et al, 2005). 
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